All News Cyxone AB

Equities

Delayed Nasdaq Stockholm Other stock markets 06:55:53 14/05/2024 pm IST			5-day change	1st Jan Change
0.102 ^SEK	-9.33%		+6.03%	+1.59%

22/04	Sweden's Cyxone Appoints New CEO	MT
22/04	Cyxone AB Announces Chief Executive Officer Changes	CI

Sweden's Cyxone Appoints New CEO	22/04	MT
Kjell Stenberg new CEO in Cyxone AB	22/04	AQ
Cyxone AB Announces Chief Executive Officer Changes	22/04	CI
BioStock: Cyxone comments on the clinical collaboration in the UK	28/03	AQ
Cyxone Enters Research Deal for Rheumatoid Arthritis Therapy	25/03	MT
Cyxone enters important research collaboration	25/03	AQ
Cyxone Enters Important Research Collaboration with University of Glasgow	25/03	CI
BioStock: Cyxone's CEO gives a status update	05/03	AQ
Cyxone AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02	CI
BioStock: Cyxone identifies target protein for rabeximod	17/01	AQ
Cyxone reaches important milestone regarding mechanism of action	15/01	AQ
Cyxone Reaches an Important Milestone for the Drug Candidate Rabeximod	15/01	CI
Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor	20/11	AQ
Interim Report 1 January to 30 September 2023	27/23/27	AQ
Cyxone AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/23/27	CI
Cyxone to Receive Unitary Patent in EU for T20K Drug Candidate	09/23/09	MT
Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K	09/23/09	AQ
BioStock Investor Meeting: Cyxone	27/23/27	AQ
Interim Report 1 January to 30 June 2023	30/23/30	AQ
Cyxone AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/23/30	CI

No results for this search